CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses

Histopathology

Volumn 46, Issue 3, 2005, Pages 328-333

  Biasoli, I ^a   Morais, J C ^a   Scheliga, A ^b   Milito, C B ^a   Romano, S ^b   Land, M ^a   Pulcheri, W ^a   Spector, Nelson ^a,c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c NONE   (Brazil)

Author keywords

Bcl 2; CD10; International Prognostic Index; Lymphoma; Prognosis

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPRILYSIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 14844309613     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02099.x     Document Type: Article

References (20)

1. Milito CB, Morais JC, Nucci M et al. Classification of non-Hodgkin's lymphoma: morphological and immunological study of 145 cases. J. Bras. Patol. Med. Lab. 2002; 38; 315-324. Available from: 〈http://www.scielo.br/scielo. php?script=sci._arttext&pid=S1676-24442002000400011&lng=en&nrm= iso〉.
2. Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia 2003; 17; 1948-1960.
3. Coiffier B. Diffuse large cell lymphoma. Curr. Opin. Oncol. 2001; 13; 325-334.
4. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993; 329; 987-994.
5. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 2002; 8; 68-74.
6. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403; 503-511.
7. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
8. Ohshima K, Kawasaki C, Muta H et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39; 156-162.
9. Huang JZ, Sanger WG, Greiner TC et al. The 1(14:18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99; 2285-2290.
10. Kramer MH, Hermans J, Wijburg E et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92; 3152-3162.
11. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90; 244-251.
12. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89; 3909-3918.
13. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia. November 1997. Mod. Pathol. 2000; 13; 193-207.
14. Barrans SL, Carter I, Owen RG et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99; 1136-1143.
15. Xu Y, McKenna RW, Molbcrg KH, Kroft SH. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am. J. Clin. Pathaol. 2001; 116; 183-190.
16. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101; 78-84.
17. Pajak TF, Clark GM, Sargent DJ, McShane LM, Hammond ME. Statistical issues in tumor marker studies. Arch. Pathol. Lab. Med. 2000; 124; 1011-1015.
18. Sáez AI, Sáez AJ, Artiga MJ et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am. J. Pathol. 2004; 164; 613-622.
19. Strehl J, Mey U, Glasmacher A et al. High dose chemotherapy followed by autologous stem cell transplantation as first line therapy in agressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003; 11; 1304-1315.
20. Slymen DJ, Miller TP, Lippman SM et al. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J. Clin. Oncol. 1990: 8; 986-993.